Crossmark

ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy

Published Online: 2021-10-11

Published Print: 2022-02

Authors

Carr, Michael J.

Zager, Jonathan S.
License Information

Text and Data Mining valid from 2021-10-11

Version of Record valid from 2021-10-11
More Information

Article History

Received: 15 September 2021

Accepted: 16 September 2021

First Online: 11 October 2021

Disclosure

: Jonathan S. Zager has advisory board relationships with Merck speaker’s bureau for Pfizer and Sun Pharma. He also receives research funding from Amgen, Delcath Systems, Philogen, Provectus and Novartis. In addition, he is a member of the speaker’s bureau for Amgen and SunPharma. Michael J. Carr has no conflicts of interest.

Document is current